COPD Therapeutics in Major Developed Markets Forecast to year 2021: 1 | Página 2

- Which classes of drug dominate the market?
- What additional benefits have newly approved therapies brought to market?
- How do the leading marketed therapies compare clinically?
The pipeline contains a range of molecule types and molecular targets, including those that are well
established in COPD, and novel, first-in-class therapies.
- Which molecular targets appear most frequently in the pipeline?
- How will the new therapies be positioned in the treatment of COPD?
- How have selected late-stage pipeline therapies performed in clinical trials?
COPD clinical trials have an overall attrition rate of 89.6%.
- What are the failure rates for individual Phases of clinical development?
- How do COPD clinical trial characteristics, including failure rate, duration, and size compare
against respiratory and industry averages?
The COPD market is forecast to rise from a value of $9.2 billion in 2014 to $11.2 billion in 2021, at a
CAGR of 2.9% across the eight major markets assessed.
- How much of a role will disease prevalence and new product approvals play in market growth?
- Will generic competition have a significant impact on the market over the forecast period?
There have been 59 licensing deals and 41 co-development deals pertaining to COPD products since
2006.
- Which territories show the most deal activity?
- What were the trends in deal completion by product stage of development?
- What were the conditions of the key licensing or co-development deals to take place in COPD?

Reasons to buy

This report will allow you to - Understand the current clinical and commercial landscape through a comprehensive study of
disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in COPD.